Document Classification

Section Type: METHODS

Text: Previously untreated patients with advanced NSCLC were randomized to receive gemcitabine-paclitaxel on a traditional three-weekly schedule (Arm A) or a novel weekly schedule (Arm B) as follows-Arm A (three-weekly) : gemcitabine 1000 mg/m2 infused > 30 min on days 1 and 8 and paclitaxel 200 mg/m2 infused > 3 h on day 1 of a 21-day cycle or Arm B (weekly) : gemcitabine 1000 mg/m2 infused > 30 min and paclitaxel 100 mg/m2 infused > 1 h, both administered on days 1 and 8 of a 21-day cycle.